Sanofi (SASY.PA) has entered into an agreement to acquire Dren Bio’s immunology unit, securing rights to its autoimmune disease treatment, DR-0201.
As part of the deal, the French pharmaceutical giant will acquire Dren Bio’s affiliate, Dren-0201, for an upfront payment of $600 million. The agreement also includes potential future milestone payments, bringing the total transaction value to $1.3 billion.
This acquisition aligns with Sanofi’s strategy to expand its immunology portfolio and strengthen its position in the autoimmune disease treatment market.
